DUBLIN--(BUSINESS WIRE)--The "Cystic Fibrosis Transmembrane Conductance Regulators (CFTR) - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.The report ...

Cystic fibrosis transmembrane conductance regulator (CFTR) is a chloride channel protein, and mutations of its gene cause cystic fibrosis. CFTR is known to be expressed in epithelial cells of the ...

Cystic fibrosis transmembrane conductance regulator gene rearrangements were searched by semiquantitative fluorescent multiplex polymerase chain reaction, which detected a CFTRdele2,3 (21 kb ...

Vertex Pharmaceuticals (VRTX) on Tuesday announced that the European Commission has granted approval for Alyftrek for the treatment of people with cystic fibrosis. The approval is for the treatment of ...

Cystic fibrosis transmembrane conductance regulator (CFTR), an anion channel expressed in both epithelial and endothelial cells, regulates the organization of tight junctions between epithelial cells ...

The cystic fibrosis transmembrane conductance regulator has been studied for years but the new efforts have yielded important insights. Scientists at St. Jude Children's Research Hospital and ...

Cystic fibrosis is caused by a genetic defect in a chloride channel called cystic fibrosis transmembrane conductase regulator. Although scientists do not fully understand how or why this defect ...

Licensed for use in the UK in March, Alyftrek will now be immediately funded by the NHS in England. This rapid timeline demonstrates NICE's commitment to getting breakthrough treatments to patients ...

Cystic fibrosis transmembrane conductance regulator (CFTR) modulators were a breakthrough for cystic fibrosis, improving the movement of chloride and water and moistening mucus secretions. But ...

Here's what cystic fibrosis is, what causes it and how it's usually treated once it has been diagnosed. Start the day smarter. Get all the news you need in your inbox each morning. What is ...

A mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene causes an excessive build-up of mucus in the lungs and dysregulated airway inflammation, making those with the ...

The FDA has expanded the indication for Kalydeco® (ivacaftor) to include treatment of cystic fibrosis in patients 4 months to less than 6 months of age. Menu SECTIONS. Home; Drug Monographs.